VivoSim Labs (FRA:4OR) LT-Debt-to-Total-Asset: 0.01 (As of Dec. 2025)

What is VivoSim Labs LT-Debt-to-Total-Asset?

VivoSim Labs FRA:4OR 39 LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.39. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. VivoSim Labs's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.01.

VivoSim Labs's long-term debt to total assets ratio declined from Dec. 2024 (0.14) to Dec. 2025 (0.01). It may suggest that VivoSim Labs is progressively becoming less dependent on debt to grow their business.

VivoSim Labs (FRA:4OR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

VivoSim Labs LT-Debt-to-Total-Asset Related Terms

VivoSim Labs LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs LT-Debt-to-Total-Asset Chart

VivoSim Labs Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.05

0.07

0.14

0.03

VivoSim Labs Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.14	0.03	0.03	0.02	0.01

39GF Score

VivoSim Labs Inc FRA:4OR

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

VivoSim Labs LT-Debt-to-Total-Asset Calculation

VivoSim Labs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )	/	Total Assets (A: Mar. 2025 )
	=	0.389	/	13.551
	=	0.03

VivoSim Labs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	0.038	/	5.944
	=	0.01

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.01 mean?

VivoSim Labs (FRA:4OR) has a LT-Debt-to-Total-Asset of 0.01 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on VivoSim Labs and its competitors.

Is VivoSim Labs' LT-Debt-to-Total-Asset too high?

VivoSim Labs' current LT-Debt-to-Total-Asset is 0.01. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.

How does VivoSim Labs' LT-Debt-to-Total-Asset compare to AZTR and GRI?

VivoSim Labs' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is VivoSim Labs stock overvalued right now?

VivoSim Labs (FRA:4OR) has a current LT-Debt-to-Total-Asset of 0.01. The stock's GF Value™ is €8.39, compared to a current price of €3.49 — trading 58.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 58.4% below its estimated GF Value™ of €8.39.

Key valuation signals for FRA:4OR:

LT-Debt-to-Total-Asset: 0.01
GF Value™: €8.39 vs. price of €3.49 (58.4% below fair value)
GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Industry Healthcare Biotechnology

Comparable Companies AZTR GRI BIXT CMND SXTP CLDI LSBCF ACUT PPCB ENSC VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges VIVS:USA

Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121

Website https://www.organovo.com

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

39GF Score

Get the complete analysis for FRA:4OR

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49

Price

€8.39

GF Value

View FRA:4OR Analysis

See LT-Debt-to-Total-Asset data for all stocks →